A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome

Journal of Neurodevelopmental Disorders

Volumn 9, Issue 1, 2017, Pages

  Ligsay, Andrew ^a,b   Van Dijck, Anke ^c,d   Nguyen, Danh V ^e,f   Lozano, Reymundo ^a,g,h   Chen, Yanjun ^f   Bickel, Erika S ^a,h   Hessl, David ^a,b   Schneider, Andrea ^a,h   Angkustsiri, Kathleen ^a,h   Tassone, Flora ^a,b   Ceulemans, Berten ^d   Kooy, R Frank ^c   Hagerman, Randi J ^a,h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adolescents; Children; Clinical trial; Fragile X syndrome; Ganaxolone

Indexed keywords

GANAXOLONE; PLACEBO;

ACNE; ADOLESCENT; AGGRESSION; ANXIETY; AORTIC DISEASE; ARTICLE; ATTENTION; AUTOMUTILATION; BURN; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DESQUAMATION; DIARRHEA; DISRUPTIVE BEHAVIOR; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; EARDRUM PERFORATION; EMOTIONAL DISORDER; EYE INFECTION; FATIGUE; FEMALE; FEVER; FRAGILE X SYNDROME; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HOT FLUSH; HUMAN; HYPERPHAGIA; HYPERSALIVATION; HYPERSOMNIA; HYPOGLYCEMIA; INCONTINENCE; INCREASED APPETITE; INTELLIGENCE QUOTIENT; INTENTION TO TREAT ANALYSIS; IRRITABILITY; KETONURIA; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MUSCULOSKELETAL INJURY; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PALLOR; PATIENT COMPLIANCE; PEDIATRIC ANXIETY RATING SCALE R; PHARYNGITIS; POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RHINORRHEA; SEIZURE; SIDE EFFECT; SKIN ABRASION; SLEEP DISORDER; SOCIAL BEHAVIOR; THIRST; TIC; TOOTH INJURY; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOCALIZATION; VOMITING; WOUND; XEROSTOMIA;

EID: 85026675364     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1186/s11689-017-9207-8     Document Type: Article

References (43)

1. Tassone F, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):100.
2. Klaiman C, et al. Longitudinal profiles of adaptive behavior in fragile X syndrome. Pediatrics. 2014;134(2):315-24.
3. Devys D, et al. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet. 1993;4(4):335-40.
4. Fernandez E, Rajan N, Bagni C. The FMRP regulon: from targets to disease convergence. Front Neurosci. 2013;7:191.
5. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370-7.
6. Gross C, et al. Therapeutic strategies in fragile X syndrome: from bench to bedside and back. Neurotherapeutics. 2015;12(3):584-608.
7. Jacquemont S, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3(64):64ra1.
8. Berry-Kravis E, et al. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med. 2016;8(321):321ra5.
9. Quiroz J, et al. Effect of two doses of Basimglurant on behavioral symptoms in adolescent & adult patients with fragile X syndrome: results from FRAGXIS, a double-blind, placebo controlled study, in International Meeting for Autism Research. Salt Lake City;2015
10. Quiroz J, et al. Safety and exploratory efficacy of Basimglurant in pediatric patients with fragile X syndrome: a randomized, double-blind, placebo-controlled study, in International Meeting for Autism Research. Salt Lake City; 2015
11. D'Hulst C, Kooy RF. Fragile X syndrome: from molecular genetics to therapy. J Med Genet. 2009;46(9):577-84.
12. Braat S, Kooy RF. Fragile X syndrome neurobiology translates into rational therapy. Drug Discov Today. 2014;19(4):510-9.
13. A receptor as a therapeutic target for neurodevelopmental disorders. Neuron. 2015;86(5):1119-30.
14. A receptors in the brain of fragile X patients. PLoS One. 2015;10(7):e0131486.
15. Braat S, et al. The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle. 2015;14(18):2985-95.
16. Braat S, Kooy RF. Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials. Neuropharmacology. 2015;88:48-54.
17. A receptor: a novel target for treatment of fragile X? Trends Neurosci. 2007;30(8):425-31.
18. D'Hulst C, et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 2009;1253:176-83.
19. Gantois I, et al. Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis. 2006;21(2):346-57.
20. D'Hulst C, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006;1121(1):238-45.
21. Heulens I, et al. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res. 2012;229(1):244-9.
22. Olmos-Serrano JL, et al. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci. 2010;30(29):9929-38.
23. Olmos-Serrano JL, Corbin JG, Burns MP. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci. 2011;33(5):395-403.
24. Carter RB, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther. 1997;280(3):1284-95.
25. Carver CM, Reddy DS. Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology (Berl). 2013;230(2):151-88.
26. Nohria V, Giller E. Ganaxolone. Neurotherapeutics. 2007;4(1):102-5.
27. Monaghan EP, et al. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia. 1997;38(9):1026-31.
28. Beekman M, et al. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. J Pharmacol Exp Ther. 1998;284(3):868-77.
29. Pieribone VA, et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia. 2007;48(10):1870-4.
30. Kerrigan JF, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000;42(2-3):133-9.
31. Tellegen PJ, Laros JA. The Snijders-Oomen nonverbal intelligence tests. General intelligence tests or tests for learning potential? In: JS Hamers K, Ruijssenaar AJJM, editors. Learning potential assessment: theoretical, methodological and practical issues. Amsterdam/Lisse: Swets & Zeitlinger B.V; 1993. p. 267-83.
32. (RUPP), the Research Units on Pediatric Psychopharmacology Anxiety Study Group. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1061-9.
33. Esbensen AJ, et al. Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. J Autism Dev Disord. 2003;33(6):617-29.
34. Sansone SM, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42(7):1377-92.
35. Swanson JM, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168-79.
36. Frolli A, Piscopo S, Conson M. Developmental changes in cognitive and behavioural functioning of adolescents with fragile-X syndrome. J Intellect Disabil Res. 2015;59(7):613-21.
37. Oblak AL, Gibbs TT, Blatt GJ. Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. Brain Res. 2011;1380:218-28.
38. Fatemi SH, et al. GABA(A) receptor downregulation in brains of subjects with autism. J Autism Dev Disord. 2009;39(2):223-30.
39. Kazdoba TM, et al. Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism. Psychopharmacology (Berl). 2016;233(2):309-23.
40. Thurman AJ, et al. Use of emotional cues for lexical learning: a comparison of autism spectrum disorder and fragile X syndrome. J Autism Dev Disord. 2015;45(4):1042-61.
41. McDuffie A, et al. Symptoms of autism in males with fragile X syndrome: a comparison to nonsyndromic ASD using current ADI-R scores. J Autism Dev Disord. 2015;45(7):1925-37.
42. Benjamin DP, et al. Effect of speaker gaze on word learning in fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder. J Speech Lang Hear Res. 2015;58(2):383-95.
43. Thurman AJ, et al. Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder. Res Dev Disabil. 2014;35(5):1072-86.